PF-Atlas › Treatments › Liver Fibrosis Reversal Protocol Crossover
Liver Fibrosis Reversal Protocol Crossover
Applying proven liver fibrosis reversal mechanisms to lung — stellate cell parallels to myofibroblast
Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Translational
Evidence level
Level 2 (Cross-domain)
Mechanism class
Applying proven liver fibrosis reversal mechanisms to lung — stellate cell parallels to myofibroblast
Timeline
2-4 years
Risk profile
Low-Medium
Developer
Icahn Sinai / Multiple
Key researchers
S. Friedman
Overview
Liver fibrosis is REVERSIBLE in humans when cause removed. Hepatic stellate cells = lung myofibroblasts. Same TGF-β/PDGF/Hedgehog pathways. Key insight: liver achieves reversal through matrix metalloproteinase activation + stellate cell apoptosis. Apply MMP activation strategy to lung.
How Liver Fibrosis Reversal Protocol Crossover fits into IPF treatment
Liver Fibrosis Reversal Protocol Crossover is classified as Level 2 (Cross-domain) at the Translational stage. Explore how it compares to other options and where it sits in the development pipeline:
Other IPF treatments
Medical disclaimer. This page summarizes published research and PF-Atlas model output about Liver Fibrosis Reversal Protocol Crossover for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.